235 related articles for article (PubMed ID: 28231414)
1. MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer.
Fukagawa S; Miyata K; Yotsumoto F; Kiyoshima C; Nam SO; Anan H; Katsuda T; Miyahara D; Murata M; Yagi H; Shirota K; Yasunaga S; Kato K; Miyamoto S
Cancer Sci; 2017 May; 108(5):886-896. PubMed ID: 28231414
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2.
Duan S; Dong X; Hai J; Jiang J; Wang W; Yang J; Zhang W; Chen C
Biomed Pharmacother; 2018 Nov; 107():712-720. PubMed ID: 30138893
[TBL] [Abstract][Full Text] [Related]
3. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
Niu Q; Liu Z; Gao J; Wang Q
Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
[TBL] [Abstract][Full Text] [Related]
4. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines.
Kazmierczak D; Jopek K; Sterzynska K; Nowicki M; Rucinski M; Januchowski R
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008952
[TBL] [Abstract][Full Text] [Related]
5. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
[TBL] [Abstract][Full Text] [Related]
6. Circular RNA circMAN1A2 promotes ovarian cancer progression through the microRNA-135a-3p/IL1RAP/TAK1 pathway.
Li B; Hu C; Zhao D; Nie M; Wang X
PeerJ; 2024; 12():e16967. PubMed ID: 38680890
[TBL] [Abstract][Full Text] [Related]
7. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
[TBL] [Abstract][Full Text] [Related]
8. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
9. miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
Cui Y; Wu F; Tian D; Wang T; Lu T; Huang X; Zhang P; Qin L
Oncol Rep; 2018 Apr; 39(4):1649-1657. PubMed ID: 29436681
[TBL] [Abstract][Full Text] [Related]
10. CircEXOC6B Suppresses the Proliferation and Motility and Sensitizes Ovarian Cancer Cells to Paclitaxel Through miR-376c-3p/FOXO3 Axis.
Zheng Y; Li Z; Yang S; Wang Y; Luan Z
Cancer Biother Radiopharm; 2022 Nov; 37(9):802-814. PubMed ID: 33006481
[No Abstract] [Full Text] [Related]
11. miRNA profile in ovarian cancer.
Ghafouri-Fard S; Shoorei H; Taheri M
Exp Mol Pathol; 2020 Apr; 113():104381. PubMed ID: 31954715
[TBL] [Abstract][Full Text] [Related]
12. miR-193b-3p possesses anti-tumor activity in ovarian carcinoma cells by targeting p21-activated kinase 3.
Zhang J; Qin J; Su Y
Biomed Pharmacother; 2017 Dec; 96():1275-1282. PubMed ID: 29169729
[TBL] [Abstract][Full Text] [Related]
13. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.
Kinose Y; Sawada K; Nakamura K; Sawada I; Toda A; Nakatsuka E; Hashimoto K; Mabuchi S; Takahashi K; Kurachi H; Lengyel E; Kimura T
Oncotarget; 2015 May; 6(13):11342-56. PubMed ID: 25839163
[TBL] [Abstract][Full Text] [Related]
14. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
Niu L; Ni H; Hou Y; Du Q; Li H
Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
[TBL] [Abstract][Full Text] [Related]
15. miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2.
Xu ZH; Yao TZ; Liu W
Biomed Pharmacother; 2018 Nov; 107():1410-1417. PubMed ID: 30257357
[TBL] [Abstract][Full Text] [Related]
16. A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer.
Wang L; Zhu MJ; Ren AM; Wu HF; Han WM; Tan RY; Tu RQ
PLoS One; 2014; 9(5):e96472. PubMed ID: 24816756
[TBL] [Abstract][Full Text] [Related]
17. let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer.
García-Vázquez R; Gallardo Rincón D; Ruiz-García E; Meneses García A; Hernández De La Cruz ON; Astudillo-De La Vega H; Isla-Ortiz D; Marchat LA; Salinas-Vera YM; Carlos-Reyes Á; López-González S; Ramos-Payan R; López-Camarillo C
Oncol Rep; 2018 Jun; 39(6):3086-3094. PubMed ID: 29658612
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
Coarfa C; Fiskus W; Eedunuri VK; Rajapakshe K; Foley C; Chew SA; Shah SS; Geng C; Shou J; Mohamed JS; O'Malley BW; Mitsiades N
Oncogene; 2016 May; 35(18):2345-56. PubMed ID: 26364608
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.
Fu X; Li Y; Alvero A; Li J; Wu Q; Xiao Q; Peng Y; Hu Y; Li X; Yan W; Guo K; Zhou W; Wang Y; Liu J; Zhang Y; Mor G; Wen J; Yin G
Oncotarget; 2016 Dec; 7(49):80633-80654. PubMed ID: 27811362
[TBL] [Abstract][Full Text] [Related]
20. miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.
Tuncer SB; Erdogan OS; Erciyas SK; Saral MA; Celik B; Odemis DA; Turkcan GK; Yazici H
J Ovarian Res; 2020 Aug; 13(1):99. PubMed ID: 32854743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
